ONCO/Reveal™
580 Genetic Test
What is ONCO/Reveal™ 580 Genetic Test?
The ONCO 580 Genetic Test Panel utilizes the Illumina platform using hybridization capture sequencing. Panel targets 580 oncogenes on all exons or some hotspots. Subsequent libraries are designed in a single-tube, multiplex reaction. With optimized reagents and enzymes, efficiency of sequence partitioning can be increased, and amplification error can be minimized. The assay contents are:
- Genetic test covering over 100 NMPA/FDA-approved drugs and targeted drugs under clinical trials.
- Thorough assessment of microsatellite instability (MSI), DNA mismatch repair (MMR), tumor mutational burden (TMB), incorporation of genes associated with PD-L1 positivity or negativity, and hyperprogression, multi-faceted prediction of efficacy of PD-1 immunotherapy.
- Integration of genomic profiling assays such as FoundationOne, MSK-IMPACT™, and TruSight Oncology (TSO) 500.
What we do for your business
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
- 1. Precise Indication for Targeted Drugs
- 2. Multi-faceted Prediction of PD-1 Inhibitors Response
- 3. Precision & Sensitivity Level
- Microsatellite Instability (MSI)
Patients with MSI status indicating potential benefits from PD-1 inhibitors.
- Tumor Mutation Burden (TMB) Assessment
Research demonstrating significant correlation between tumor mutation burden (TMB) and efficacy of anti-PD-1/PD-L1.
- Mismatch Repair (MMR) Associated Genes Testing
Providing consideration to anti-PD-1 treatment for patients tested with deficient mismatch repair (dMMR) after the failure of standard treatment.
- Microsatellite Instability (MSI)
Patients with MSI status indicating potential benefits from PD-1 inhibitors.
- Tumor Mutation Burden (TMB) Assessment
Research demonstrating significant correlation between tumor mutation burden (TMB) and efficacy of anti-PD-1/PD-L1.
- Mismatch Repair (MMR) Associated Genes Testing
Providing consideration to anti-PD-1 treatment for patients tested with deficient mismatch repair (dMMR) after the failure of standard treatment.
et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.